Lüchtenberg Marc, Bartel Jan Hendrik, Bink Andrea, Kuhli-Hattenbach Claudia, Berkefeld Joachim
Department of Ophthalmology, Johann Wolfgang Goethe University, Frankfurt am Main, Germany.
Ophthalmologica. 2007;221(6):434-8. doi: 10.1159/000107507.
Balloon dacryocystoplasty (DCP) is known to have limited clinical success rates. In a previous publication, we tried to define subgroups that could benefit from interventional treatment of tear duct stenoses. The purpose of this study was to evaluate the clinical effectiveness of DCP performed with limited indication confined to patients with circumscribed stenosis or distal occlusion of the nasolacrimal duct (NLD).
Twenty-nine patients with severe epiphora due to dacryocystographically proven postsaccal obstruction of the lacrimal draining system were treated by means of DCP and were available for a telephone interview after a median follow-up period of 40 months (5-75 months). A standardized questionnaire covered the individual history of epiphora before and after interventional treatment. All patients had circumscribed stenoses of the lower lacrimal sac or the NLD or presented with short-distance occlusions of the distal NLD. Patients with canalicular, high saccal or diffuse lesions as well as cases with active dacryocystitis, suspicion of dacryocystolithiasis or posttraumatic stenosis were excluded from DCP. Failures or recurrences with no major improvement compared with the initial status were taken as a study endpoint.
We dilated 21 partial and 8 complete obstructions and post-DCP control dacryocystograms showed a widening of the ductal lumen or improvement of flow. In 25 out of 29 patients, regression of clinical symptoms occurred during the first week after treatment, 4 cases remained unchanged. Ten out of 25 patients with initial improvement reported recurrence of severe epiphora after a median period of 5 months. Five patients of all treated patients (n = 29) received additional operative dacryocystorhinostomy (DCR) after failure of DCP or due to severe recurrences. One patient received DCR during the 1st week after DCP (n = 1). Four out of 25 patients with initial improvement underwent DCR. Overall, 15 of the 29 treated patients had durable improvement of epiphora by DCP alone.
Even patients with circumscribed obstructions of the NLD and exclusion of factors potentially associated with poor outcome of tear duct stenosis after DCP balloon dilatation showed a limited clinical success and high recurrence rate. The main argument to continue DCP as first or second line treatment in selected patients with duct obstructions is its lack of invasiveness. Even patients with increased risk of general anesthesia can be treated and approximately half of the operations may be avoided.
球囊泪囊成形术(DCP)的临床成功率有限。在之前的一篇出版物中,我们试图确定能从泪道狭窄介入治疗中获益的亚组。本研究的目的是评估DCP的临床有效性,其适应证仅限于泪囊狭窄或鼻泪管(NLD)远端阻塞的患者。
29例经泪囊造影证实泪道引流系统泪囊后段阻塞导致严重溢泪的患者接受了DCP治疗,在中位随访期40个月(5 - 75个月)后可进行电话访谈。一份标准化问卷涵盖了介入治疗前后溢泪的个人病史。所有患者均有泪囊下段或NLD的局限性狭窄,或表现为NLD远端的短距离阻塞。泪小管、泪囊上段或弥漫性病变患者,以及患有急性泪囊炎、怀疑泪囊结石或创伤后狭窄的病例被排除在DCP治疗之外。与初始状态相比无明显改善的失败或复发情况被作为研究终点。
我们扩张了21处部分阻塞和8处完全阻塞,DCP术后对照泪囊造影显示管腔增宽或引流改善。29例患者中有25例在治疗后第一周临床症状消退,4例无变化。25例初始症状改善的患者中有10例在中位5个月后报告严重溢泪复发。所有接受治疗的患者(n = 29)中有5例在DCP失败或因严重复发后接受了额外的手术泪囊鼻腔吻合术(DCR)。1例患者在DCP后第1周接受了DCR(n = 1)。25例初始症状改善的患者中有4例接受了DCR。总体而言,29例接受治疗的患者中有15例仅通过DCP获得了持久的溢泪改善。
即使是NLD局限性阻塞且排除了DCP球囊扩张后泪道狭窄预后不良潜在相关因素的患者,临床成功率也有限且复发率高。在选定的泪道阻塞患者中继续将DCP作为一线或二线治疗的主要理由是其无创性。即使是全身麻醉风险增加的患者也可以接受治疗,并且大约可以避免一半的手术。